2α-Methyl-19-nor-(20S)-1,25-dihydroxyvitamin D 3 protects the insulin 2 knockout non-obese diabetic mouse from developing type 1 diabetes without hypercalcaemia

Clinical and Experimental Immunology

Volumn 166, Issue 3, 2011, Pages 325-332

  Kiekhaefer, C M ^a   Weber, B ^a   Huggins, M ^a   Gorichanaz, C ^a   Nehring, J A ^a   Deluca, H F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Beta cells; Insulin 2 knock out NOD mice; Islets of Langerhans; T cells; Type 1 diabetes

Indexed keywords

2ALPHA METHYL 19 NOR (20) 1,25 DIHYDROXYVITAMIN D3; CALCITRIOL; INSULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DESTRUCTION; CELL INVASION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENCY; FEMALE; GLUCOSE TOLERANCE TEST; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; INTRAPERITONEAL GLUCOSE TOLERANCE TEST; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; CALCITRIOL; CALCIUM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; FEMALE; GENOTYPE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; MICE, KNOCKOUT;

EID: 80855144625     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04481.x     Document Type: Article

References (29)

1. Pearl-Yafe M, Kaminitz A, Yolcu ES, Yaniv I, Stein J, Askenasy N. Pancreatic islets under attack: cellular and molecular effectors. Curr Pharm Des 2007; 13:749-60.
2. McDevitt HO, Unanue ER. Autoimmune diabetes mellitus - much progress, but many challenges. Adv Immunol 2008; 100:1-12.
3. Azam A, Eisenbarth GS. Immunopathogenesis and immunotherapeutic approaches to type 1A diabetes. Exp Opin Biol Ther 2004; 4:1569-75.
4. Babaya N, Nakayama M, Eisenbarth GS. The stages of type 1A diabetes. Ann NY Acad Sci 2005; 1051:194-204.
5. Eisenbarth GS, Jeffrey J. The natural history of type 1A diabetes. Arq Bras Endocrinol Metabol 2008; 52:146-55.
6. Tsai EB, Sherry NA, Palmer JP, Herold KC, Grp D-S. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 2006; 49:261-70.
7. Babaya N, Nakayama M, Eisenbarth GS. The stages of type 1A diabetes. Ann NY Acad Sci 2005; 1051:194-204.
8. Liu E, Eisenbarth GS. Type 1A diabetes mellitus-associated autoimmunity. Endocrinol Metab Clin North Am 2002; 31:391-410
9. Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev 2005; 204:232-49.
10. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358:221-9.
11. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999; 5:601-4.
12. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23:447-85.
13. Aoki CA, Borchers AT, Ridgway WM, Keen CL, Ansari AA, Gershwin ME. NOD mice and autoimmunity. Autoimmun Rev 2005; 4:373-9.
14. Leiter EH. Nonobese diabetic mice and the genetics of diabetes susceptibility. Curr Diab Rep 2005; 5:141-8.
15. Yang Y, Santamaria P. Lessons on autoimmune diabetes from animal models. Clin Sci (Lond) 2006; 110:627-39.
16. Giarratana N, Penna G, Adorini L. Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse. Methods Mol Biol 2007; 380:285-311.
17. Wicker LS, Clark J, Fraser HI etal. Type 1 diabetes genes and pathways shared by humans and NOD mice. J Autoimmun 2005; 25:29-33.
18. von Herrath M, Chan A. How can we improve the translational landscape for a faster cure of type 1 diabetes? J Clin Invest 2009; 119:1061-5.
19. von Herrath M, Nepom GT. Animal models of human type 1 diabetes. Nat Immunol 2009; 10:129-32.
20. Dubois-Lafforgue D, Mogenet L, Thebault K, Jami J, Krief P, Boitard C. Proinsulin 2 knockout NOD mice-a model for genetic variation of insulin gene expression in type 1 diabetes. Diabetes 2002; 51:S489-S493.
21. Heath VL, Moore NC, Parnell SM, Mason DW. Intrathymic expression of genes involved in organ specific autoimmune disease. J Autoimmun 1998; 11:309-18.
22. Pleau JM, Esling A, Geutkens S, Dardenne M, Homo-Delarche F. Pancreatic hormone and glutamic acid decarboxylase expression in the mouse thymus: a real-time PCR study. Biochem Biophys Res Commun 2001; 283:843-8.
23. Chentoufi AA, Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes 2002; 51:1383-90.
24. Pugliese A, Zeller M, Fernandez A Jr etal. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997; 15:293-7.
25. Vafiadis P, Bennett ST, Todd JA etal. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997; 15:289-92.
26. Thebault-Baumont K, Dubois-Laforgue D, Krief P etal. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 2003; 111:851-7.
27. 3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem 1998; 41:4662-74.
28. Suda T, DeLuca HF, Tanaka Y. Biological activity of 25-hydroxyergocalciferol in rats. J Nutr 1970; 100:1049-52.
29. Smith SM, Levy NS, Hayes CE. Impaired immunity in vitamin D-deficient mice. J Nutr 1987; 117:857-65.